Natalie R. Schwarber, PharmD

• Infectious Diseases Clinical Pharmacist, HSHS St. John�s Hospital, Springfield
• Adjunct Clinical Instructor, Southern Illinois University Edwardsville School of Pharmacy, Edwardsville, Illinois

Stage 2 disease is characterized by exposed bone with associated pain cholesterol eggs or cheese simvastatin 40 mg for sale, adjacent or regional soft tissue inflammatory swelling why so much cholesterol in shrimp simvastatin 10 mg cheap, or secondary infection cholesterol levels what is high buy simvastatin 10mg online. Stage 3 disease is characterized by exposed bone associated with pain cholesterol levels very high order 5 mg simvastatin otc, adjacent or regional soft tissue inflammatory swelling cholesterol free eggs substitutes cheap simvastatin 20 mg amex, or secondary infection cholesterol definition and importance order simvastatin 40 mg line, in addition to a pathologic fracture, an extraoral fistula or oral-antral fistula, or radiographic evidence of osteolysis extending to the inferior border of the mandible or the floor of the maxillary sinus. Before and after any surgical procedures involving bone, patients should rinse with chlorhexidine twice daily for 4 to 8 weeks after surgery. Orthodontics: Reports have shown an increase in tooth movement in patients taking bisphosphonates; patients should be advised of this potential complication; the duration of orthodontic treatment may be prolonged and uniform tooth movement may be compromised. Implant placement and maintenance: Bisphosphonate treatment does not impact implant placement or maintenance, except in extensive cases; treatment should continue as planned. Management of periodontal disease: Patients who have active periodontal disease should receive appropriate forms of nonsurgical therapy. Endodontics: Endodontic treatment is preferable to surgical manipulation if the tooth is salvageable. Limited evidence shows that periapical healing after endodontic therapy is similar regardless of bisphosphonate use. The Medical Consultants of Consumer Reports On-Health Bulletin reported an incidence of one case for every 20,000 users of oral bisphosphonates (0. The true risk posed by oral bisphosphonates remains uncertain but appears to be very small. Is the risk of acquiring osteonecrosis of the jaw bone diminished with the use of other oral bisphosphonates compared to Fosamax Among the class of oral bisphosphonates, more cases have been associated with Fosamax than with Actonel or Boniva. Zoledronic acid under the band name of Reclast has recently been approved as a once-annual, 15-minute intravenous infusion of a dose of 5 mg to prevent osteoporosis. This dosing was associated with a significant improvement in bone mineral density and bone metabolism markers. Will Fosamax or the other oral bisphosphonates continue to be the standard treatment for osteoporosis The oral bisphosphonates continue to be the most effective class of drugs in reducing the risk of osteoporotic fractures and are the first-line therapy in the treatment of osteoporosis. Fosamax has been shown to prevent bone loss at the spine and hip in postmenopausal women and to reduce fractures by ~50%. This question has not been answered and information is only speculative at this time. Osteoporosis can occur due to age-related changes in the number of osteoclasts and bone resorption sites. This overwhelms the production of new bone by osteoblasts and a decrease in bone mass occurs. By inhibiting osteoclastic activity, the oral bisphosphonates seemingly arrest the osteoporotic syndrome. In the process, however, the maxilla and mandible, upon continued exposure to the bisphosphonates, exhibit delayed wound healing following injury from mechanical forces or invasive surgery, such as tooth extraction. This coupled with the antiangiogenic effect (ie, a reduction in bone blood supply by the bisphosphonates) may contribute to jaw bone necrosis. Ruggiero and Drew have suggested that a preferential deposition of the bisphosphonates in the mandible and maxilla may contribute to the necrosis appearing within the jaw rather than within bones outside the craniofacial skeleton. The use of chronic steroids such as prednisone has been identified as a risk factor. Other factors are periodontitis, smoking, wearing dentures, diabetes, and the duration of exposure and age, with longer treatment regimens and age >65 years associated with a greater risk of developing the disease (Hellstein 2011). Patients identified with jaw bone necrosis typically were exposed to oral bisphosphonates for 2 years or longer. What are the symptoms that an oral bisphosphonates patient would experience which could indicate necrotic jaw bone Clinical symptoms would include a nonhealing extraction site, exposed bone surrounded by inflamed soft tissue, and purulent discharge at site of exposed bone. Exposed bone is usually more prevalent in areas such as the tori and the mylohyoid ridge. According to the American Dental Association, all routine procedures can be carried out. Routine dental treatment should not be modified on the basis of oral bisphosphonate use. However, the presence of risk factors, such as steroid use, >65 years of age, or prolonged exposure to oral bisphosphonates, may require consultation with an expert in metabolic bone disease prior to routine dental treatment. In asymptomatic patients receiving oral bisphosphonate therapy, dentoalveolar surgery is not contraindicated. Also surgery common to periodontists and other dental providers need not be delayed. In patients about to begin oral bisphosphonate therapy, should the bisphosphonate be delayed until dental health is optimized It does not appear necessary for patients to initiate prophylactic dental treatment prior to initiating oral bisphosphonate therapy for osteoporosis. It would be prudent, however, to encourage these patients to maintain an optimal level of dental health. It has been reported that panoramic and periapical radiographs probably will not reveal significant changes in early stages of osteonecrosis and they are poor screening tools for prediction. Evidence does suggest, however, that such an association may exist, particularly with intravenous bisphosphonate use in cancer patients. It is estimated that 22 to 30 million prescriptions were written for alendronate (Fosamax), the most widely used oral bisphosphonate in the United States, between May 2003 and April 2004. For many years, dental implants have been placed in many patients taking oral bisphosphonates. It is important to remember that any beneficial or detrimental effects of these drug holidays have not been prospectively studied. Dental implant, if elected, can be placed in the patient about to begin oral bisphosphonate therapy. However, informed consent concerning the potential for implant loss and/or exposed bone related to the bisphosphonates should be obtained as the patient continues bisphosphonate therapy and exceeds 3 years of continuous use. For individuals who have taken an oral bisphosphonate for <3 years and have no clinical or radiographic risk factors, no alteration or delay is necessary for planned dental surgeries. For patients who have taken an oral bisphosphonates for >3 years, it is advised that the prescribing physician be contacted and a recommendation made to discontinue the oral bisphosphonate for 3 months prior to the procedure and refrain from reinstating use until 3 months after the procedure. Scully et al, suggested that when possible, extractions should be avoided in patients receiving oral bisphosphonates and it is best to avoid all elective surgery in these patients, including endosseous implant placement, or treatment should be performed well in advance prior to bisphosphonate therapy. If surgery is performed on patients taking bisphosphonates, they must be counseled about the risk. This study, out of the Dentistry/Oral Surgery Group at Montefiore Medical Center, Albert Einstein College of Medicine, reported that of 115 patients taking oral bisphosphonates, none showed evidence or had symptoms of osteonecrosis after implant placement. This report had findings similar to a previous report by Dr Jeffcoat, who showed success in implant placement and no signs of necrosis in patients taking oral bisphosphonates. The Montefiore study, by Grant et al, used a survey to collect information from patients who had received dental implants and were taking oral bisphosphonates. The study, reported in the Journal of Oral and Maxillofacial Surgery, identified 1,319 female patients >40 years of age who had implant surgery between January 1998 and December 2006. A survey was mailed to each of these individuals asking about current and past use of oral bisphosphonates. From those returned, 115 individuals reported taking oral bisphosphonates before or after implant surgery. In this population, it was then determined that a total of 468 implants had been placed in the 115 individuals. This population that responded to the survey was then compared to a random sample of individuals who did not respond with regard to age and number of implants. It was found that only five among 100 nonresponders to the survey had a history of bisphosphonate use compared to the 115 of the 458 responders. The remaining 343 patients indicated that they had not received bisphosphonate therapy. From the pool of 458 responders, there were 1,450 implants placed in these patients and 1,436 had integrated successfully. It was found that 466 of those implants were in function and were considered successful. In one case of failure, the patient had taken oral bisphosphonates for 3 years prior to implant placement but no longer was taking any drug at the time of implant placement or thereafter. The investigators removed and replaced the implant and it was still in function for >4 years. In the second case, the patient had been taking bisphosphonates for >8 years and the failure occurred in one implant out of a total of 13 in place. She also reported success in implant placement and no signs of necrosis in patients taking oral bisphosphonates. Her method was a single blind controlled study using 50 postmenopausal female dental implant patients. Twenty-five had taken oral bisphosphonates for 1-4 years and the other 25 patients did not take oral bisphosphonates prior to or during the study. In the bisphosphonate group, there was a total of 102 implants that were placed and in the nondrug group, there were 108 implants that were placed. After 3 years, there was 100% success rate with no evidence of infection, pain, or necrosis in patients receiving bisphosphonates. A further review of the literature found only two cases of dental implant failure associated with oral bisphosphonate use. One was a case report from 1995 that suggested that failure of five implants was caused by bisphosphonate therapy. In that case, five implants were placed and successfully integrated in the mandible. The patient then began bisphosphonate therapy 28 months after implant placement and after 4 months, a panoramic radiograph revealed osteolysis around all implants and all five were removed one month later. In the report by Wang et al, a patient developed a significant bone defect with necrosis after proper implant placement. Four weeks later, upon evaluation, bone defects were observed and noted around two of the implants. The defects were repaired with mineralized human cancellous bone mixed with tetracycline and covered with collagen membrane. Eventually after some further antibiotics and chlorhexidine daily rinsing, complete uneventful healing occurred. Marx used Quest Diagnostics Nichols East Lab in San Juan Capistrano California to perform the analysis on the samples. According to Ruggiero and Drew, low bone turnover in the jaw due to osteoclastic inhibition by bisphosphonates results in the inability of the bone to repair local microdamage from normal mechanical loading or injury. A dental examination with appropriate preventive dentistry should be considered prior to initiating denosumab treatment in patients with concomitant risk factors. These patients should avoid invasive dental procedures if possible during treatment with denosumab. Use clinical judgement and guide the management plan of each patient based on individual risk:benefit evaluation. The treating physician should guide the management plan of each patient based on individual benefit:risk assessment and communication with the dentist. Patients should be educated on maintaining excellent oral hygiene to reduce the risk of need for invasive procedures in the future. Patients should check and adjust removable appliances such as prostheses to avoid soft tissue injury. Routine cleaning should be performed with care, attempting to reduce any soft tissue injury; however, since hygiene is important, the normal recall planning and treatment should continue. Endodontic therapy is preferable to extractions; treatment with endodontics followed by coronal amputation and root canal therapy on the retained roots may be necessary. Only minimal bony debridement to reduce sharp and rough surfaces to prevent further trauma to adjacent or opposing tissues is recommended. A removable appliance or protective stent may be used to protect exposed bone or adjacent tissues. Before discontinuing bisphosphonate therapy, patient should be evaluated for potential risk of further osteonecrosis versus the risk of skeletal complications. Patients should be cautioned regarding gastrointestinal side effects with long-term use of any antibiotic. Rx: Clindamycin (Systemic) 300 mg capsules Disp: 40 capsules Sig: Take 1 capsule 3 or 4 times/day for 7 to 10 days Note: Prescription usually selected for patients allergic to penicillin; may be prescribed for 3 or 4 times/day. This prescription can be continued for >1 month; however, risk of Clostridioides (formerly Clostridium) difficile colitis increases. Patients should be cautioned to take clindamycin with food and monitor for gastrointestinal side effects with long-term use. Osteonecrosis of the jaw in patients treated with denosumab: a multicenter case series. Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs.

Talking with other cancer survivors can be especially helpful for the newly diagnosed cholesterol levels chart in uk purchase generic simvastatin canada. Some support groups welcome patients who have any form of cancer; others are dedicated to just one form of the disease cholesterol medication pregnancy simvastatin 5 mg generic. Specifically kresser cholesterol ratio generic simvastatin 5 mg otc, providers may believe (incorrectly) that dosage should be low because (1) older adults are relatively insensitive to pain; (2) if pain occurs cholesterol bad foods cheap simvastatin 20mg overnight delivery, older adults can tolerate it well; and (3) older adults are highly sensitive to opioid side effects cholesterol granuloma generic simvastatin 20 mg with amex. The first two concepts have no basis in fact and therefore must not be allowed to influence treatment cholesterol medication blood sugar cost of simvastatin. Although there is some truth to the third concept, concern about side effects is no excuse for inadequate dosing. Increased Risk of Side Effects and Adverse Interactions For several reasons, older adult patients may experience more side effects than younger adults. As noted, drug elimination in older adults is impaired, posing a risk that drug levels may rise dangerously high. However, with careful dosing, drug levels can be kept within a range that is both safe and effective. Gastric erosion can be reduced by concurrent therapy with misoprostol or a proton pump inhibitor. The risk of serious injury from drug interactions can be reduced by careful drug selection and by monitoring for potential reactions. Paradoxically, a third issue-heightened drug sensitivity- contributes to both problems. Young Children Management of cancer pain in children is much like management in adults. In addition, children frequently experience more pain from chemotherapy and other interventions than from the cancer itself. Heightened Drug Sensitivity Older adults are more sensitive to drugs than are younger adults, owing largely to a decline in organ function. As a result, drugs tend to accumulate in the body, causing responses to be more intense and prolonged. In addition to the usual reasons (fears about tolerance, addiction, adverse effects, and regulatory actions), older adults are denied adequate medication for two more reasons: difficulties with assessment and erroneous ideas about "old age. Because of these obstacles, special effort must be made to help ensure that assessment is accurate. Selecting an appropriate assessment method is especially important for children with developmental delays, learning disabilities, and emotional disturbances. Assessment can be greatly facilitated by open communication about pain between the child, family, and healthcare team. Assessment methods include self-reporting, behavioral observation, and measurement of physiologic parameters. As stressed earlier, self-reporting is preferred and should be employed whenever appropriate. Because many factors other than pain can alter physiologic parameters, measuring these is the least reliable way to assess pain. These include (1) fear that revealing their pain will lead to additional injections and other painful procedures, (2) lack of awareness that healthcare workers can help their pain go away, (3) a desire to protect their parents from the knowledge that their cancer is getting worse, and (4) a desire to please. Because the self-report may conceal pain, it can be helpful to supplement the self-report with behavioral observation (see later in this section). Because preverbal and nonverbal children cannot self-report pain, a less reliable method must be used for assessment. Behavioral cues suggesting pain include vocalization (crying, whining, groaning), facial expression (grimacing, frowning, reduced affect), muscle tension, inability to be consoled, protection of body areas, and reduced activity. The biggest drawback to behavioral observation is the risk of a false-negative conclusion. That is, a child may be in pain although his or her behavior may lead the observer to conclude otherwise. Similarly, although sitting quietly might indicate comfort, it could also mean that moving and talking are painful. When behavioral observation leaves doubt about whether the child is in pain, a trial with an analgesic can help confirm the assessment. Treatment Therapy of cancer pain in children is essentially the same as in adults. As in adults, drugs are the cornerstone of treatment; nondrug therapies are used only as supplements. More invasive routes should be reserved for patients who cannot take drugs by mouth. Children generally object to rectal administration and may refuse treatment by this route. Neonates and infants are highly sensitive to drugs, and hence must be treated with special caution. Because of heightened drug sensitivity, neonates and infants are at increased risk of respiratory depression from opioids. Accordingly, when opioids are given to nonventilated infants, the initial dosage should be very low (about one-third the dosage employed for older children). Furthermore, use of opioids should be accompanied by intensive monitoring of respiration. Because of the challenge, treatment should be directed by a clinician trained in substance abuse as well as pain management. Remember, patients who abuse opioids feel pain like everyone else and therefore need opioids like everyone else. Clinicians must take special care not to withhold opioids because they have confused relief-seeking behavior with drug-seeking behavior. Hence, if the patient tells us that pain is persisting, adequate doses of opioids should be provided. Because of opioid tolerance, initial doses in patients with opioid use disorder must be higher than in patients who do not abuse opioids. To estimate how high the initial dosage should be, we must try to estimate the existing degree of tolerance by interviewing the patient about the extent of opioid use. However, because regulations limit the dosage of methadone that drug-abuse clinics can dispense, the increased dosage required to manage pain will have to come from another source. One group of opioids-the agonist-antagonists-will precipitate withdrawal in opioid abusers, and hence must never be prescribed for these patients. When education is successful, it can help reduce anxiety, dispel hopelessness, facilitate assessment, enhance compliance, decrease complications, provide a sense of control, and enable patients to take an active role in their care. General Issues Common sense tells us that patient education should be accurate, comprehensive, and understandable. To reinforce communication, information should be presented at least twice and in more than one way. Major topics to discuss are (1) the nature and causes of pain, (2) assessment and the importance of honest self-reporting, and (3) plans for drug and nondrug therapy. Patients should be encouraged to express their fears and concerns about cancer, cancer pain, and pain treatment-and they should be reassured that pain can be effectively controlled in most cases. To facilitate ongoing education, patients should be invited to contact care providers whenever they feel the need-be it to discuss specific Opioid Use Disorder When treating cancer pain in patients with opioid use disorder, we have two primary obligations: we must try to (1) relieve the pain and (2) avoid giving opioids simply because the patient wants to get high. Finally, patients should know when and how to contact the prescriber to report treatment failure, serious side effects, or new pain. Drug Therapy the goal in teaching patients about analgesic drugs is to maximize pain relief and minimize harm. When pain is persistent, as it is for most patients, the objective is to prevent pain from returning. Hence, patients should be taught what drug and dosage to use for rescue treatment. Fears based on misconceptions about opioids can impair compliance and can thereby impair pain control. The misconceptions that influence compliance the most relate to tolerance, physical dependence, addiction, and side effects. Hence, to help ensure pain relief in the future, they limit opioid use now and thus suffer needless pain. These patients should be reassured that if tolerance does develop, efficacy can be restored by increasing the dosage; tolerance does not mean that efficacy is lost. This fear is based largely on the misconception that physical dependence (which eventually develops in all patients) equals addiction. Patients should be taught that physical dependence is not the same as addiction and that physical dependence itself is nothing to fear. In addition, they should be taught that the behavior pattern that constitutes addiction rarely develops in people who take opioids in a therapeutic setting. These patients should be reassured that when used correctly, opioids are both safe and effective. With all of the adjuvants, the objective is to complement the effects of opioid and nonopioid analgesics. Furthermore, because the drugs we use as adjuvants were originally developed to treat disorders other than pain, the rationale for prescribing specific adjuvants should be explained. For example, when duloxetine is prescribed, the patient should understand that the objective is to relieve neuropathic pain and not depression, the disorder for which this drug was originally developed. Basic issues related to patient education in drug therapy are discussed in Chapter 2. Nondrug Therapy Education regarding nondrug therapy focuses on psychosocial interventions. Patients should understand that these interventions are intended as complements to analgesics-not as alternatives. Techniques for imagery, relaxation, and distraction should be introduced early in treatment. Family caregivers should be taught how to apply heat and cold and how to give a therapeutic massage. Patients should be informed about the benefits of peer support groups and given assistance in locating one. Under the standards, accountability for pain management is shifted from individual practitioners to the institution as a whole. Compliance is mandatory: Healthcare organizations that fail to meet the standards will lose accreditation. Loss of accreditation would mean loss of insurance reimbursement and would disqualify teaching hospitals from offering training programs. It should be noted that the standards are not a guideline on how to treat specific kinds of pain. Rather, they focus on (1) the rights of patients to receive appropriate assessment and management of pain, and (2) ways for institutions to establish a formalized, systematic approach to pain management that involves interdisciplinary teams whose members have clearly identified responsibilities. Despite the availability of effective treatments, cancer pain goes unrelieved in a large number of patients. Barriers to pain relief include inadequate prescriber training, fears of addiction, and a healthcare system that until recently has put a low priority on pain management. Pain has two major forms: nociceptive pain, which results from injury to tissues, and neuropathic pain, which results from injury to peripheral nerves. Management of cancer pain is an ongoing process that involves repeated cycles of assessment, intervention, and reassessment. The goal is to create an individualized treatment plan that can meet the changing needs of the patient. Behavioral observation is a poor substitute for the patient self-report as a method of assessment. If pain is already intense, treatment can start with an opioid, rather than trying a nonopioid first. Because nonopioids and opioids relieve pain by different mechanisms, combining an opioid with a nonopioid can be more effective than either drug alone. Because acetaminophen does not affect platelets, the drug is safe for patients with thrombocytopenia. Opioids are the most effective analgesics available, and hence are the primary drugs for treating moderate to severe cancer pain. Opioids are especially effective against nociceptive pain; efficacy against neuropathic pain is limited. There is a ceiling to pain relief with the agonist-antagonists, but not with the pure agonists. Oral administration is preferred for most patients; transdermal administration is a good alternative. An equianalgesia table can facilitate dosage selection when switching from one opioid to another or from one route to another. Over time, opioids cause tolerance, a state in which a specific dose produces a smaller effect than it could when treatment began. Tolerance develops to analgesia, euphoria, respiratory depression, and sedation, but not to constipation or miosis. Over time, opioids produce physical dependence, a state in which an abstinence syndrome will occur if the drug is abruptly withdrawn. Misconceptions about opioid addiction are a major cause for undertreatment of cancer pain. Accordingly, we must correct these misconceptions by teaching physicians, nurses, patients, and family members that (1) addiction is not the same as physical dependence, and (2) addiction is very rare in therapeutic settings. Severe respiratory depression can be reversed with naloxone [Narcan], an opioid antagonist.

For phenobarbital and other barbiturates that are excreted intact in the urine high cholesterol fat foods discount simvastatin uk, forced diuresis and alkalinization of the urine may facilitate their renal excretion cholesterol vap test order simvastatin once a day. Not only are stimulants ineffective cholesterol lowering foods ireland generic simvastatin 5 mg amex, they are also dangerous: Their use in barbiturate poisoning has been associated with a significant increase in mortality cholesterol medication bad breath buy simvastatin online now. Naloxone cholesterol in food bad buy simvastatin overnight delivery, a drug that can reverse poisoning by opioids inergy cholesterol medication buy simvastatin american express, is not effective against poisoning by barbiturates. Patients should be warned not to increase their dosage or to discontinue treatment without consulting the prescriber. Intravenous administration is reserved for general anesthesia and emergency treatment of convulsions. Injections should be made slowly to minimize respiratory depression and hypotension. Blood pressure, pulses, and respiration should be monitored, and facilities for resuscitation should be available. Extravasation may result in local necrosis, hence care must be taken to ensure that extravasation does not occur. Intra-arterial injection should be avoided, owing to a risk of gangrene secondary to prolonged arteriospasm. Injection in the vicinity of peripheral nerves can cause irreversible neurologic injury. Barbiturates reduce ventilation by two mechanisms: (1) depression of brainstem neurogenic respiratory drive and (2) depression of chemoreceptive mechanisms that control respiratory drive. Doses only 3 times greater than those needed to induce sleep can cause complete suppression of the neurogenic respiratory drive. For most patients, the degree of respiratory depression produced at therapeutic doses is not significant. However, in older adult patients and in those with respiratory disease, therapeutic doses can compromise respiration substantially. Because of their toxicity, the barbiturates are employed as vehicles for suicide, and hence should not be dispensed to patients with suicidal tendencies. The barbiturates that are most prone to abuse are those in the short- to intermediate-acting group. Although barbiturates are frequently abused in nonmedical settings, they are rarely abused during medical use. Some people have difficulty falling asleep, some have difficulty maintaining sleep, some are troubled by early morning awakening, and some have sleep that is not refreshing. In any given year, about 30% of Americans experience intermittent insomnia, and about 10% experience chronic insomnia. As a result of sleep loss, insomniacs experience daytime drowsiness along with impairment of mood, memory, coordination, and the ability to concentrate and make decisions. Chronic insomnia is a major risk factor for automotive and industrial accidents, marital and social problems, major depression, coronary heart disease, and metabolic and endocrine dysregulation. Sleep is frequently lost owing to concern regarding impending surgery and other procedures. Major life stressors (bereavement, divorce, loss of job) frequently disrupt sleep. Other factors, such as uncomfortable bedding, excessive noise, and bright light, can rob us of sound sleep. Acute Toxicity Acute intoxication with barbiturates is a medical emergency: Left untreated, overdose can be fatal. Poisoning is often the result of attempted suicide, although it can also occur by accident (usually in children and drug abusers). Acute overdose produces a classic triad of symptoms: respiratory depression, coma, and pinpoint pupils. Accordingly, if therapy is to succeed, the underlying reason for sleep loss must be determined. When the cause of insomnia is a known medical disorder, primary therapy should be directed at the underlying illness; hypnotics should be employed only as adjuncts. For example, if pain is the reason for lost sleep, analgesics should be prescribed. If insomnia is secondary to major depression, antidepressants are the appropriate treatment. Nondrug Therapy For many insomniacs, nondrug measures may be all that is needed to promote sleep. For some individuals, avoidance of naps and adherence to a regular sleep schedule are sufficient. If environmental factors are responsible for lack of sleep, the patient should be taught how to correct them or compensate for them. All patients should be counseled about sleep fitness (also known as sleep hygiene). Research has shown that cognitive behavioral therapy is superior to drug therapy for both short-term and long-term management of chronic insomnia in older adults. Cognitive and behavioral interventions include sleep restriction, control of the bedroom environment, progressive relaxation, and education about sleep hygiene. The American Academy of Sleep Medicine considers these interventions both effective and reliable, and hence recommends them as first-line therapy for chronic insomnia, even if drug therapy is also employed. Therapy With Hypnotic Drugs Hypnotics should be used only when insomnia cannot be managed by other means. Hence, before resorting to drugs, we should implement nondrug measures, and we should treat any pathology that may underlie inadequate sleep. The patient should be reassessed on a regular basis to determine whether drug therapy is still needed. This will help condition your brain to see the bedroom as a place where sleep happens. If hypnotic effects are lost in the course of treatment, it is preferable to interrupt therapy rather than to elevate dosage. Interruption will allow tolerance to decline, thereby restoring responsiveness to treatment. Patients who snore heavily and those with respiratory disorders have reduced respiratory reserve, which can be further compromised by the respiratory-depressant actions of hypnotics. Hypnotic agents are generally contraindicated for use during pregnancy; these drugs have the potential to cause fetal harm, and their use is rarely an absolute necessity. When hypnotics are employed, care must be taken to prevent drug-dependency insomnia, a condition that can lead to inappropriate prolongation of therapy. Upon cessation of treatment, a mild withdrawal syndrome occurs and disrupts sleep. Failing to recognize that the inability to sleep is a manifestation of drug withdrawal, the patient becomes convinced that insomnia has returned and resumes drug use. Continued drug use leads to heightened physical dependence, making it even more difficult to withdraw medication without producing another episode of drug-dependency insomnia. That is, they should be used in the lowest effective dosage for the shortest time required. Drugs such as flurazepam, which have both a rapid onset and long duration, are good for patients with both types of sleep problems. Major Hypnotics Used for Treatment Insomnia can be treated with prescription drugs, nonprescription drugs, and alternative medicines. Among the prescription drugs, benzodiazepines and the benzodiazepine-like drugs (zolpidem, zaleplon, and eszopiclone) are drugs of choice. Nonprescription Benzodiazepines Benzodiazepines are drugs of first choice for short-term treatment of insomnia. These agents are safe and effective and lack the undesirable properties that typify barbiturates and other older hypnotics. Benzodiazepines have a low abuse potential, cause minimal tolerance and physical dependence, present a minimal risk of suicide, and undergo few interactions with other drugs. Only five benzodiazepines are marketed specifically for use as hypnotics (see Table 34. Benzodiazepines have multiple desirable effects on sleep: they decrease the interval to sleep onset, decrease the number of awakenings, and increase total sleeping time. Two agents-triazolam [Halcion] and flurazepam-can be considered prototypes of the benzodiazepines used to promote sleep. Triazolam has a rapid onset and short duration, making it a good choice for patients who have difficulty in falling asleep (as compared with difficulty in maintaining sleep). Flurazepam has a delayed onset and more prolonged duration, making it an effective agent for patients who have difficulty in maintaining sleep. However, because flurazepam has a relatively long half-life, the drug is likely to cause daytime drowsiness, and hence is not used widely today. Triazolam has a much shorter half-life than flurazepam, which is both good news and bad news. The good news is that because it leaves the body rapidly, triazolam does not cause daytime sedation. The bad news is that because triazolam is rapidly cleared, treatment is associated with two problems: (1) tolerance to hypnotic effects can develop quickly-in 11 to 18 days, which is much faster than with other benzodiazepines, and (2) triazolam causes more rebound insomnia than other benzodiazepines. Ramelteon does not cause tolerance or dependence, and is not regulated as a controlled substance. Suvorexant Suvorexant [Belsomra] is an orexin receptor antagonist approved for both onset and maintenance of sleep. The drug can decrease sleep latency and prolong sleep duration, and does not cause tolerance or physical dependence. In clinical trials of adults with chronic insomnia, Silenor increased total sleep time and maintained the effect for over 12 weeks. The initial dosage for patients age 65 and older is 3 mg, taken within 30 minutes of bedtime. Both dosages are much lower than the dosages used for depression (75 to 150 mg/day). The most common adverse effects are sedation, nausea, and upper respiratory infection. In the high doses used for depression, doxepin can cause hypotension, dysrhythmias, and anticholinergic effects. Owing to the risk of anticholinergic effects, Silenor is contraindicated for patients with untreated narrow-angle glaucoma or severe urinary retention. In addition, Silenor is contraindicated for patients who have taken a monoamine oxidase inhibitor within the past 2 weeks. Unlike the benzodiazepines and benzodiazepine-like drugs, Silenor has little or no potential for abuse, and hence is not regulated under the Controlled Substances Act. In fact, one of these drugs-zolpidem-is prescribed more often than any other hypnotic. All three drugs have the same mechanism as the benzodiazepines-and all three are as effective as the benzodiazepines, and may be safer for long-term use. Furthermore, whereas benzodiazepines are contraindicated during pregnancy, the benzodiazepine-like drugs are not (although use during pregnancy should be discouraged). All three drugs have a rapid onset, and hence can help people with difficulty in falling asleep. Also, with zolpidem and eszopiclone, effects persist long enough to help people who have difficulty in staying asleep. In contrast, effects of zaleplon fade too rapidly to help people with trouble in staying asleep. Owing to its ultrashort duration, zaleplon can be taken a few hours before rising and still not cause drowsiness during the day. However, even though long-term studies for zaleplon and zolpidem are lacking, it seems likely that they too would retain efficacy when taken long term. The pharmacology of the benzodiazepine-like drugs is discussed previously in this chapter. Ramelteon Ramelteon [Rozerem] is a melatonin agonist approved for long-term therapy of insomnia. These drugs are less effective than benzodiazepines and benzodiazepine-like drugs, and tolerance develops quickly (in 1 to 2 weeks). Alternative Medicines Of the alternative medicines employed to promote sleep, only one-melatonin- appears moderately effective (see Box 34. Several others-valerian root, chamomile, passionflower, lemon balm, and lavender-have very mild sedative effects, but proof of benefits in insomnia is lacking. Although benzodiazepines can cause physical dependence, the withdrawal syndrome is usually mild (except in patients who have undergone prolonged high-dose therapy). To minimize withdrawal symptoms, benzodiazepines should be discontinued gradually, over several weeks or even months. Although benzodiazepines undergo extensive metabolism, in most cases the metabolites are pharmacologically active. As a result, responses produced by administering a particular benzodiazepine often persist long after the parent drug has disappeared from the blood. All of the benzodiazepines have essentially equivalent pharmacologic actions; hence, selection among them is based in large part on differences in time course. The principal indications for benzodiazepines are anxiety, insomnia, and seizure disorders. The principal adverse effects of benzodiazepines are daytime sedation and anterograde amnesia. Rarely, patients taking benzodiazepines to promote sleep carry out sleep driving and other complex behaviors, and then have no memory of their actions. Flumazenil, a benzodiazepine receptor antagonist, can be used to treat benzodiazepine overdose.

Pseudocholinesterase activity can be assessed by direct measurement of a blood sample or by administering a tiny test dose of succinylcholine cholesterol deposits 20mg simvastatin amex. If the test dose produces muscle relaxation that is unexpectedly intense and prolonged cholesterol levels after quitting smoking cheap simvastatin 40 mg free shipping, pseudocholinesterase activity is probably low ldl cholesterol level definition discount simvastatin 40 mg visa. Malignant hyperthermia is a rare and potentially fatal condition that can be triggered by succinylcholine cholesterol ldl hdl discount 40 mg simvastatin. Other manifestations include cardiac dysrhythmias measuring cholesterol in eggs buy simvastatin 20 mg with mastercard, unstable blood pressure lots of cholesterol in eggs buy cheap simvastatin, electrolyte derangements, and metabolic acidosis. Malignant hyperthermia is a genetically determined reaction that has an incidence of about 1 in 25,000. Individuals with a family history of the reaction should not receive succinylcholine. From 10% to 70% of patients receiving succinylcholine experience postoperative muscle Prolonged Apnea in Patients With Low Pseudocholinesterase Activity. A few people, because of their genetic pain, most commonly in the neck, shoulders, and back. Pain develops 12 to 24 hours after surgery and may persist several hours or even days. The cause may be the muscle contractions that occur during the initial phase of succinylcholine action. Significant hyperkalemia is most likely to occur in patients with major burns, multiple trauma, denervation of skeletal muscle, or upper motor neuron injury. Cholinesterase inhibitors decrease the activity of pseudocholinesterase, the enzyme that inactivates succinylcholine. Note that the effect of cholinesterase inhibitors on succinylcholine is opposite to their effect on competitive neuromuscular blockers. Among these are aminoglycosides, tetracyclines, and certain other nonpenicillin antibiotics. Because there is no specific antidote to succinylcholine poisoning, management is purely supportive. Recall that paralysis from overdose with a competitive agent can be reversed with a cholinesterase inhibitor. Because cholinesterase inhibitors delay the degradation of succinylcholine, use of these agents would prolong-not reverse-succinylcholine toxicity. Preparations, Dosage, and Administration Succinylcholine chloride [Anectine, Quelicin] is available in solution. All of the competitive agents in current use are indicated for muscle relaxation during general anesthesia, mechanical ventilation, and intubation. Succinylcholine is used primarily for muscle relaxation during intubation and electroconvulsive therapy, and rarely for other short procedures. Muscle Relaxation During Surgery Production of muscle relaxation during surgery offers two benefits. Second, muscle relaxants allow us to decrease the dosage of the general anesthetic, thereby decreasing the risks associated with anesthesia. Before neuromuscular blockers became available, surgical muscle relaxation had to be achieved with the general anesthetic alone, often requiring high levels of anesthetic. By allowing a reduction in anesthetic levels, neuromuscular blockers have decreased the risk of complications from anesthesia and hastened recovery from anesthesia. Whenever neuromuscular blockers are employed during surgery, it is very, very important that anesthesia be maintained at a level sufficient to produce unconsciousness. Neuromuscular blockers are obviously and definitely not a substitute for anesthesia. It does not require much imagination to appreciate the horror of the surgical patient who is completely paralyzed from neuromuscular blockade yet fully awake because of inadequate anesthesia. Clearly, full anesthesia must be provided whenever surgery is performed on a patient who is under neuromuscular blockade. With the agents in current use, full recovery from surgical neuromuscular blockade takes about an hour. During the recovery period, patients must be monitored closely to ensure adequate ventilation. As you can imagine, being fully awake but completely paralyzed can be a stressful and horrific experience. Accordingly, many clinicians do not recommend routine use of neuromuscular blockers during prolonged mechanical ventilation in intensive care units. It is essential for the nurse to administer prescribed medications such as sedatives and/or analgesics on a regular basis to prevent undue suffering. Endotracheal Intubation An endotracheal tube is a large catheter that is inserted past the glottis and into the trachea to facilitate ventilation. Because of its short duration of action, succinylcholine is the preferred agent for this use, although all of the competitive agents are also approved for this use. Facilitation of Mechanical Ventilation Some patients who require mechanical ventilation still have some spontaneous respiratory movements, which can fight the rhythm of the respirator. By suppressing these movements, neuromuscular blocking agents can reduce resistance to ventilation. When neuromuscular blockers are used to facilitate mechanical ventilation, patients should be treated as if they were awake-even though they appear to be asleep. Adjunct to Electroconvulsive Therapy Electroconvulsive therapy is an effective treatment for severe depression (see Chapter 32). Benefits derive strictly from the effects of electroshock on the brain; the convulsive movements that can accompany electroshock do not have a role in relieving depression. Because convulsions per se serve no useful purpose and because electroshock-induced convulsions can be harmful, a neuromuscular blocker is now used to prevent convulsive movements during electroshock therapy. Because of its short duration of action, succinylcholine is the preferred neuromuscular blocker for this application. Neuromuscular blockers interfere with nicotinicM receptor activation, and thereby cause muscle relaxation. Competitive neuromuscular blockers act by competing with acetylcholine for binding to nicotinicM receptors. Succinylcholine, the only depolarizing neuromuscular blocker in use, binds to nicotinicM receptors, causing the end-plate to depolarize; the drug then remains bound, which keeps the end-plate from repolarizing. Neuromuscular blockers are used to produce muscle relaxation during surgery, endotracheal intubation, mechanical ventilation, and electroshock therapy. Cholinesterase inhibitors can reverse the effects of competitive neuromuscular blockers but will intensify the effects of succinylcholine. Accordingly, effects are greatly prolonged in patients with low plasma cholinesterase activity. Preadministration Assessment Therapeutic Goal Provision of muscle relaxation during surgery, endotracheal intubation, mechanical ventilation, electroconvulsive therapy, and other procedures. Identifying High-Risk Patients Use all neuromuscular blockers with caution in patients with myasthenia gravis. Succinylcholine is contraindicated for patients with low pseudocholinesterase activity, a personal or familial history of malignant hyperthermia, or conditions that predispose to hyperkalemia (major burns, multiple trauma, denervation of skeletal muscle, upper motor neuron injury). Administration Neuromuscular blockers should be administered by clinicians skilled in their use. Implementation: Measures to Enhance Therapeutic Effects Neuromuscular blockers do not affect consciousness or perception of pain. When neuromuscular blockers are used for prolonged paralysis during a mechanical ventilation, care should be taken to ensure comfort. Facilities for intubation and mechanical ventilation should be immediately available. When drug administration is discontinued, take vital signs frequently, according to policy, until recovery is complete. A cholinesterase inhibitor can be used to reverse respiratory depression caused by competitive neuromuscular blockers, but not by succinylcholine, a depolarizing blocker. Succinylcholine can cause severe hyperkalemia resulting in cardiac arrest if given to patients with major burns, multiple trauma, denervation of skeletal muscle, or upper motor neuron injury. Certain antibiotics, including aminoglycosides and tetracyclines, can intensify neuromuscular blockade. These drugs delay inactivation of succinylcholine, thereby greatly prolonging paralysis. Accordingly, cholinesterase inhibitors are contraindicated for patients receiving succinylcholine. We begin with the general mechanisms by which drugs can activate adrenergic receptors. Next we establish an overview of the major adrenergic agonists, focusing on their receptor specificity and chemical classification. After that, we address the adrenergic receptors themselves; for each receptor type-alpha1, alpha2, beta1, beta2, and dopamine-we discuss the beneficial and harmful effects that can result from receptor activation. Finally, we integrate all of this information by discussing the characteristic properties of representative sympathomimetic drugs. Our objective is to discuss the basic properties of the sympathomimetic drugs and establish an overview of their applications and adverse effects. In later chapters, we will discuss the clinical applications of these agents in greater depth. Direct Receptor Binding Direct interaction with receptors is the most common mechanism by which drugs activate peripheral adrenergic receptors. Since the sympathetic nervous system acts through these same receptors, responses to adrenergic agonists and responses to stimulation of the sympathetic nervous system are very similar. Because of this similarity, adrenergic agonists are often referred to as sympathomimetics. Adrenergic agonists have a broad spectrum of indications, ranging from heart failure to asthma to preterm labor. Agents that act by this mechanism include cocaine and the tricyclic antidepressants. Catecholamines the catecholamines are so named because they contain a catechol group and an amine group. A catechol group is simply a benzene ring that has hydroxyl groups on two adjacent carbons. Because of their chemistry, all catecholamines have three properties in common: (1) they cannot be used orally, (2) they have a brief duration of action, and (3) they cannot cross the blood-brain barrier. Both enzymes are very active and quickly destroy catecholamines administered by any route. Because these enzymes are located in the liver and intestinal wall, catecholamines that are administered orally become inactivated before they can reach the systemic circulation. Be aware that catecholamine-containing solutions, which are colorless when first prepared, turn pink or brown over time. The only exception is dobutamine, which can be used up to 24 hours after the solution was made, even if discoloration appears. As a result, the half-lives of noncatecholamines are much longer than those of catecholamines. Third, noncatecholamines are considerably less polar than catecholamines, and hence are more able to cross the blood-brain barrier. Accordingly, if we know to which category a particular adrenergic agonist belongs, we will know three of its prominent features. Receptor Specificity To understand the actions of individual adrenergic agonists, we need to know their receptor specificity. Epinephrine is even less selective, acting at all four adrenergic receptor subtypes: alpha1, alpha2, beta1, and beta2. The receptor specificities of the major adrenergic agonists are shown in Table 17. In the upper part of the table, receptor specificity is presented in tabular form. By learning this content, you will be well on your way to understanding the pharmacology of the sympathomimetic drugs. The ability of a drug to selectively activate certain receptors to the exclusion of others depends on the dosage: at low doses, selectivity is maximal; as dosage increases, selectivity declines. For example, when albuterol is administered in low to moderate doses, the drug is highly selective for beta2adrenergic receptors. Arrows indicate the range of receptors that the drugs can activate (at usual therapeutic doses). So-called selective agents will activate additional adrenergic receptors if the dosage is abnormally high. Because many adrenergic agonists activate more than one type of receptor (see Table 17. Consequently, rather than attempting to structure this presentation around representative drugs, we discuss the actions of the adrenergic agonists one receptor at a time. Our discussion begins with alpha1 receptors, and then moves to alpha2 receptors, beta1 receptors, beta2 receptors, and finally dopamine receptors. For each receptor type, we discuss both the therapeutic and adverse responses that can result from receptor activation. To understand the effects of any specific adrenergic agonist, all you need is two types of information: (1) the identity of the receptor(s) at which the drug acts and (2) the effects produced by activating those receptors. This is the same approach to understanding neuropharmacologic agents that we discussed in Chapter 12. We are about to discuss the clinical consequences of adrenergic receptor activation, and Table 13. If you choose not to memorize Clinical Consequences of Alpha1 Activation In this section we discuss the therapeutic and adverse effects that can result from activation of alpha1-adrenergic receptors. Therapeutic Applications of Alpha1 Activation Activation of alpha1 receptors elicits two responses that can be of therapeutic use: (1) vasoconstriction (in blood vessels of the skin, viscera, and mucous membranes), and (2) mydriasis. Of the two, vasoconstriction is the one for which alpha1 agonists are used most often.

Order simvastatin 40 mg. Carnivore Diet: Why would it work? What about Nutrients and Fiber?.